All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-02-08T12:17:03.000Z

DA-EPOCH-R versus R-CHOP for double hit DLBCL

Feb 8, 2019
Share:

Bookmark this article

On 10 January 2019, Anna Dodero and Anna Guidetti from the Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, IT, and colleagues published in Leukemia a retrospective study investigating the efficacy and safety of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in double-hit diffuse large B-cell lymphoma (DLBCL) patients.

In this retrospective study the outcomes of DLBCL double expressors were compared after DA-EPOCH-R or R-CHOP treatment, which was administered in a similar period in three different Italian institutions. The primary endpoints of this study were progression-free survival (PFS), and overall survival (OS). Secondary endpoints included survival comparisons according to different subgroup analyses (age, genetic abnormalities etc.). 

Study design & baseline characteristics 

  • N = 114 double-hit DLBCL patients
  • Patients were treated with either:
    • DA-EPOCH-R (n = 51)
    • R-CHOP (n = 63)
  • Dosing:
    • DA-EPOCH-R (n = 51; six 21-cycles):
      • Etoposide: 50 mg/m2 intravenously (IV) on Day 1, 2, 3, and 4
      • Doxorubicin: 10 mg/m2 IV on Day 1, 2, 3, and 4
      • Vincristine: 0.4 mg/m2 IV on Day 1, 2, 3, and 4
      • Cyclophosphamide: 750 mg/m2 IV on Day 5
      • Prednisone: 60 mg/m2 orally on Day 1, 2, 3, 4 and 5
    • R-CHOP (n = 63): usual dosing every 21 days
  • Central nervous system (CNS) prophylaxis was administered when necessary according to institutional guidelines
    • Patients in the R-CHOP group received less CNS prophylaxis (30%) than those in the DA-EPOCH-R group (96%)
  • All patients underwent computed tomography (CT) scan, positron emission tomography scan (PET), bone marrow (BM) biopsy and diagnostic lumbar puncture, including cytological and immunophenotypic analyses at baseline
  • An intermediate CT was performed after 3−4 DA-EPOCH-R or R-CHOP cycles
    • Patients exhibiting a less than partial response (PR) or disease progression (PD) were moved to second line regimens according to institutional guidelines
  • Clinical response evaluation was performed at the end of treatment cycle 6 by CT, PET, and BM biopsy
  • Disease assessment was performed at follow-up (three month intervals) for the first two years; every six months until the fifth year; annually thereafter
  • Baseline characteristics were well balanced between the two groups 

Key findings

  • CNS relapses:
    • DA-EPOCH-R: n = 1 patient
    • R-CHOP: n = 3 patients
  • Consolidative radiotherapy administration:
    • DA-EPOCH-R: 21% of patients
    • R-CHOP: 35% of patients
  • DA-EPOCH-R group median follow-up: 20 months
  • R-CHOP group median follow-up: 49 months
  • Two-year PFS (before inverse probability of treatment weight [IPTW] Cox modelling):
    • DA-EPOCH-R: 62% (95% CI, 45−84%)
    • R-CHOP: 54% (95% CI, 43−69%)
  • Two-year OS (before IPTW Cox modelling):
    • DA-EPOCH-R: 85% (95% CI, 74−98%)
    • R-CHOP: 70% (95% CI, 60−83%)
  • Two-year PFS (after IPTW Cox modelling):
    • DA-EPOCH-R: 57%
    • R-CHOP: 51%
    • Comparison: P = 0.198
  • Two-year OS (after IPTW Cox modelling):
    • DA-EPOCH-R: 90%
    • R-CHOP: 67%
    • Comparison: P = 0.07
  • IPTW Cox modelling was used to investigate the effect of patient age, International Prognostic Index (IPI) or DLBCL molecular subgroup on patient outcomes:
    • Age was the only statistically significant influencing variable. In patients aged < 65 years:
    • DA-EPOCH-R:
      • PFS: 82% (95% CI, 66−100%)
      • OS: 90% (95% CI, 74−100%)
    • R-CHOP:
      • PFS: 43% (95% CI, 26−73%)
      • OS: 62% (95% CI, 43−88%)
    • PFS comparison: P = 0.02
    • OS comparison: P = 0.04

Safety

  • Death occurred in:
    • DA-EPOCH-R: 12% of patients (n = 6)
      • PD: n = 4
      • Pneumonia: n = 1
      • Suicide: n = 1
    • R-CHOP: 35% of patients (n = 22)
      • PD: n = 20 patients
      • Drug toxicity: n = 2 patients
    • Treatment discontinuation due to adverse events (AEs) occurred in:
      • DA-EPOCH-R: n =2 patients (pneumonia [Grade 5] and infection [alive patient in CR])
      • R-CHOP: n = 2 patients (both Grade 5 drug toxicity)
    • EPOCH dose adjustment was performed successfully in the majority of patients aged ≤ 65 years (73% of patients escalated to ≥ 3 dose level). However, the majority of patients > 65 years received only dose level one of EPOCH

Conclusions

  • Age and genetic abnormalities play a key role in patient outcomes of DLBCL double expressors
  • DA-EPOCH-R treatment was associated with a better PFS than R-CHOP in young double-hit DLBCL patients (< 65 years old)
  • DA-EPOCH-R treatment was associated with a better OS than R-CHOP in young double-hit DLBCL patients (< 65 years old)
  • Patient subgroup analysis for genetic abnormalities revealed that DA-EPOCH-R leads to a better PFS than R-CHOP in such patient populations
  1. Dodero A. and Guidetti A. et al. Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia. 2019 Jan 10. DOI: 10.1038/s41375-018-0320-9 [Epub ahead of print].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox